BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25799134)

  • 1. Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
    Sie M; den Dunnen WF; Lourens HJ; Meeuwsen-de Boer TG; Scherpen FJ; Zomerman WW; Kampen KR; Hoving EW; de Bont ES
    PLoS One; 2015; 10(3):e0122555. PubMed ID: 25799134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines.
    Zomerman WW; Plasschaert SL; Diks SH; Lourens HJ; Meeuwsen-de Boer T; Hoving EW; den Dunnen WF; de Bont ES
    PLoS One; 2015; 10(10):e0141381. PubMed ID: 26496080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
    Geoerger B; Gaspar N; Opolon P; Morizet J; Devanz P; Lecluse Y; Valent A; Lacroix L; Grill J; Vassal G
    Int J Cancer; 2008 Jul; 123(1):209-16. PubMed ID: 18386816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
    Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
    J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic inhibition of cell migration by tetraspanin CD82 and gangliosides occurs via the EGFR or cMet-activated Pl3K/Akt signalling pathway.
    Li Y; Huang X; Zhang J; Li Y; Ma K
    Int J Biochem Cell Biol; 2013 Nov; 45(11):2349-58. PubMed ID: 23968914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
    Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
    Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor and hepatocyte growth factor cooperate to enhance cell proliferation, scatter, and invasion in murine mammary epithelial cells.
    Accornero P; Miretti S; Starvaggi Cucuzza L; Martignani E; Baratta M
    J Mol Endocrinol; 2010 Feb; 44(2):115-25. PubMed ID: 19850646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.
    Gürsel DB; Connell-Albert YS; Tuskan RG; Anastassiadis T; Walrath JC; Hawes JJ; Amlin-Van Schaick JC; Reilly KM
    Neuro Oncol; 2011 Jun; 13(6):610-21. PubMed ID: 21636709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
    He S; Dibas A; Yorio T; Prasanna G
    Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
    Murphy DA; Makonnen S; Lassoued W; Feldman MD; Carter C; Lee WM
    Am J Pathol; 2006 Nov; 169(5):1875-85. PubMed ID: 17071608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
    Jane EP; Premkumar DR; Pollack IF
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
    Karajannis MA; Legault G; Fisher MJ; Milla SS; Cohen KJ; Wisoff JH; Harter DH; Goldberg JD; Hochman T; Merkelson A; Bloom MC; Sievert AJ; Resnick AC; Dhall G; Jones DT; Korshunov A; Pfister SM; Eberhart CG; Zagzag D; Allen JC
    Neuro Oncol; 2014 Oct; 16(10):1408-16. PubMed ID: 24803676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.
    Feres KJ; Ischenko I; Hayman MJ
    Oncogene; 2009 Jan; 28(2):279-88. PubMed ID: 18836480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.
    Matsuda Y; Wakai T; Kubota M; Osawa M; Hirose Y; Sakata J; Kobayashi T; Fujimaki S; Takamura M; Yamagiwa S; Aoyagi Y
    Int J Clin Exp Pathol; 2014; 7(4):1299-313. PubMed ID: 24817927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.